Literature DB >> 10492360

Evaluation of intraoperative radiation therapy for unresectable pancreatic cancer with FDG PET.

T Higashi1, H Sakahara, T Torizuka, Y Nakamoto, S Kanamori, M Hiraoka, M Imamura, Y Nishimura, N Tamaki, J Konishi.   

Abstract

UNLABELLED: This investigation was undertaken to evaluate 18F-labeled fluorodeoxyglucose (FDG) PET in monitoring patients after intraoperative radiotherapy (IORT) for unresectable pancreatic cancer and to compare its usefulness with CT.
METHODS: FDG PET was performed in 12 consecutive unresectable ductal adenocarcinoma patients before (n = 12) and after IORT (0.7-11.9 mo, n = 14). In the follow-up period, FDG PET results after IORT were divided into three groups: early (0-2.0 mo after IORT, n = 7), intermediate (2.1-4.0 mo, n = 5) and delayed period (4.1 mo or later, n = 2). FDG uptake at 60 min after injection of 185 MBq FDG under fasting conditions was analyzed with standardized uptake value (SUV). Three parameters, the highest SUV in the tumor, the area of tumor showing SUV of more than 2.0 and the average SUV in the tumor area were calculated. Ratios of each parameter after IORT to that before IORT were defined as residual uptake ratio (RUR)-1, -2 and -3, respectively. Tumor regression after IORT was evaluated with CT as tumor size ratio (TSR) every 2 mo.
RESULTS: Results of RUR-1 and -3 were consistent with tumor size measured by CT. They decreased in 10 patients with partial response and increased in 2 patients with no change, although these 2 patients had abscesses. RUR-3 decreased consistently as 0.65+/-0.33 in 2 mo, 0.51+/-0.39 in 4 mo and 0.24 in 4 mo or later after IORT, respectively. RUR-1 decreased in early period, but demonstrated no change through the remaining periods. There were discrepancies between the results of RUR-2 and those of the other RURs. CT results revealed a slow decrease in tumor size, because TSR was 0.91 +/-0.10, 0.76+/-0.11 and 0.70+/-0.18 in 2, 4 and 6 mo after IORT, respectively. RUR-3 was smaller than TSR at 2 mo (P < 0.05) and 4 mo (P = 0.056). These results indicate that the measurement of the average SUV in the tumor area with FDG PET could evaluate the local response of pancreatic cancer after IORT earlier and more markedly than with CT.
CONCLUSION: FDG PET was useful in monitoring patients after IORT, because the decrease of metabolism in pancreatic tumor could be detected earlier than the decrease in tumor size.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10492360

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  4 in total

1.  Is quantitation necessary for oncological PET studies? Against.

Authors:  Michael M Graham
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-01       Impact factor: 9.236

2.  (18)F-FDG PET/CT imaging detects therapy efficacy of anti-EMMPRIN antibody and gemcitabine in orthotopic pancreatic tumor xenografts.

Authors:  Nemil Shah; Guihua Zhai; Joseph A Knowles; Cecil R Stockard; William E Grizzle; Naomi Fineberg; Tong Zhou; Kurt R Zinn; Eben L Rosenthal; Hyunki Kim
Journal:  Mol Imaging Biol       Date:  2012-04       Impact factor: 3.488

3.  Imaging of the pancreas: Recent advances.

Authors:  Vikas Chaudhary; Shahina Bano
Journal:  Indian J Endocrinol Metab       Date:  2011-07

4.  FDG-PET in the prediction of survival of patients with cancer of the pancreas: a pilot study.

Authors:  N R Maisey; A Webb; G D Flux; A Padhani; D C Cunningham; R J Ott; A Norman
Journal:  Br J Cancer       Date:  2000-08       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.